A hormone that holds promise for a dramatically more effective treatment of type 2 diabetes, a metabolic illness afflicting millions of people was discovered by Harvard researchers.
The researchers at the Harvard Stem Cell Institute (HSCI) believe that the hormone might also have a role in treating type 1, or juvenile, diabetes.
Diabetes Screening
Diabetes screening is done using blood tests like fasting blood sugar and hemoglobin A1c levels. Diabetes affects 8.3% Americans and about 10% Indians.
Advertisement
The hormone, called betatrophin, causes mice to produce insulin-secreting pancreatic beta cells at up to 30 times the normal rate. The new beta cells only produce insulin when called for by the body, offering the potential for the natural regulation of insulin and a great reduction in the complications associated with diabetes, the leading medical cause of amputations and non-genetic loss of vision.
The researchers who discovered betatrophin, HSCI co-director Doug Melton and postdoctoral fellow Peng Yi, caution that much work remains to be done before it could be used as a treatment in humans. But the results of their work, which was supported in large part by a federal research grant, already have attracted the attention of drug manufacturers.
![Type 2 Diabetes]( "Type 2 Diabetes")
Globalization and changing lifestyles has made diabetes very common in developing countries so much so that India is known as the Diabetes Capital of the World.
"If this could be used in people," said Melton, Harvard's Xander University Professor and co-chair of the University's Department of Stem Cell and Regenerative Biology, "it could eventually mean that instead of taking insulin injections three times a day, you might take an injection of this hormone once a week or once a month, or in the best case maybe even once a year."
"Our idea here is relatively simple," Melton said. "We would provide this hormone, the type 2 diabetic will make more of their own insulin-producing cells, and this will slow down, if not stop, the progression of their diabetes. I've never seen any treatment that causes such an enormous leap in beta cell replication."
Though Melton sees betatrophin primarily as a treatment for type 2 diabetes, he believes it might play a role in the treatment of type 1 diabetes as well, perhaps boosting the number of beta cells and slowing the progression of that autoimmune disease when it's first diagnosed.
While Melton was clear about the need for more research before the hormone could be available as a drug, he also said that betatrophin could be in human clinical trials within three to five years, an extremely short time in the normal course of drug discovery and development.
The work was published by the journal Cell as an early on-line release.
Source: ANI
Type 2 Diabetes
Globalization and changing lifestyles has made diabetes very common in developing countries so much so that India is known as the Diabetes Capital of the World.
Advertisement
"If this could be used in people," said Melton, Harvard's Xander University Professor and co-chair of the University's Department of Stem Cell and Regenerative Biology, "it could eventually mean that instead of taking insulin injections three times a day, you might take an injection of this hormone once a week or once a month, or in the best case maybe even once a year."
"Our idea here is relatively simple," Melton said. "We would provide this hormone, the type 2 diabetic will make more of their own insulin-producing cells, and this will slow down, if not stop, the progression of their diabetes. I've never seen any treatment that causes such an enormous leap in beta cell replication."
Though Melton sees betatrophin primarily as a treatment for type 2 diabetes, he believes it might play a role in the treatment of type 1 diabetes as well, perhaps boosting the number of beta cells and slowing the progression of that autoimmune disease when it's first diagnosed.
While Melton was clear about the need for more research before the hormone could be available as a drug, he also said that betatrophin could be in human clinical trials within three to five years, an extremely short time in the normal course of drug discovery and development.
The work was published by the journal Cell as an early on-line release.
Source: ANI
Diabetes and Exercise
Regular exercise especially in type II diabetes not only helps reduce the sugar but also reduces the demand for medication by 20% and helps you stay healthy.
Advertisement
 Diabetes Type 2 and Its Link to Sugar-Sweetened BeveragesSugar-sweetened beverages contribute to metabolic syndrome leading to higher risk for type-2 diabetes and cardiovascular disease. | Advertisement
|
Advertisement
Recommended Readings
Latest Diabetes News
Individuals with type 2 diabetes benefit from exposure to daylight over artificial light, leading to improved blood sugar control.
Scientists have elucidated the mechanisms through which prediabetes can be induced to enter remission, resulting in the restoration of normal blood glucose levels.
The survival rates of white patients with multiple myeloma and diabetes were lower than those without diabetes but in black patients.
Recent study underscores tirzepatide's supremacy over semaglutide in regulating blood sugar and achieving weight loss.
Physical activity or exercise in the morning and afternoon reduces type 2 diabetes risk, whereas evening exercise has no such association.
